Hair loss and potential treatments, primarily focusing on Finasteride and Minoxidil. Other solutions discussed include PRP, dermarolling, LLP, and scalp tension relief.
The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.
A user discusses a company, Roots by Genetic Arts, that offers a genetic test for hair loss to create personalized treatments, and is curious about its legitimacy and the science behind it. The company tests 16 genes related to hair loss and compounds a topical treatment based on the results.
A 26-year-old discusses hair loss treatment using oral finasteride microdosing, topical minoxidil with tretinoin, and dermastamping every 10 days. They started experiencing hair loss at 19 and have been using these treatments for 8 months.
Hair transplants in Bangkok are praised for their natural appearance, with a zigzag hairline design being favored over straight lines. The clinic Hairtran and Dr. Patty receive positive feedback, though some users express skepticism about photo filters and the authenticity of results.
The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.
Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.
A user questioning if they've lost any hair between 2020 and 2023 without using any treatments. They also inquire if a doctor can determine hair loss just by looking, recalling a past suggestion of platelet rich plasma treatment.
The user switched from finasteride to dutasteride for hair loss treatment, also using topical minoxidil, micro needling, keto shampoo, and PRP sessions. They've seen improvements, with reduced hair shedding and new hair growth, especially at the hairline.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.
Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.
A 32-year-old male with Norwood 3 and heavy diffuse thinning is starting a hair loss treatment including RU58841, Minoxidil, finasteride, derma rolling, vitamins, and possibly MK677, while cutting out most sugars from his diet. He plans to share progress photos and updates on his test levels.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
The user is treating androgenetic alopecia with finasteride and discovered a folic acid deficiency. They are asking if curing the deficiency can worsen or improve their hair condition.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
Placebo hair regrowth might be influenced by propylene glycol in lotions or participants lying about using other treatments like minoxidil, finasteride, or microneedling. Being part of a study can also improve hair health due to lifestyle changes.
Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.
A user suggests making a potent sulforaphane topical to degrade DHT and promote hair growth. Another user notes that sulforaphane's low molecular weight might also lower systemic DHT.
The user has been using Dutasteride for over a year for hair loss and is considering a hair transplant if it doesn't work. Suggestions include adding Minoxidil and microneedling, but some advise against a transplant as the current treatment seems effective.
A 38-year-old male with stress-induced Telogen Effluvium is seeking advice on using oral finasteride and minoxidil, as well as vitamin regimens, for hair loss. He is considering these treatments after a dermatologist ruled out male pattern baldness and prescribed ketoconazole shampoo.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
A 23-year-old plans a hair transplant and uses finasteride, Essengen 6 Plus, ketoconazole shampoo, dermarolling, vitamins, and Foligain capsules. He seeks advice on his regimen and the timing of the procedure, considering family history and potential future hair loss.
The user is experiencing diffuse hair loss due to high testosterone levels and has tried various treatments including finasteride, minoxidil, nanoxidil, keto/caffeine shampoo, dermarolling, and RU-58841 with limited success. They are seeking advice on safely lowering testosterone levels to manage hair loss.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.
PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.
The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.